These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
417 related articles for article (PubMed ID: 21867911)
1. Discovery of kibdelomycin, a potent new class of bacterial type II topoisomerase inhibitor by chemical-genetic profiling in Staphylococcus aureus. Phillips JW; Goetz MA; Smith SK; Zink DL; Polishook J; Onishi R; Salowe S; Wiltsie J; Allocco J; Sigmund J; Dorso K; Lee S; Skwish S; de la Cruz M; Martín J; Vicente F; Genilloud O; Lu J; Painter RE; Young K; Overbye K; Donald RG; Singh SB Chem Biol; 2011 Aug; 18(8):955-65. PubMed ID: 21867911 [TBL] [Abstract][Full Text] [Related]
2. Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities. Singh SB; Goetz MA; Smith SK; Zink DL; Polishook J; Onishi R; Salowe S; Wiltsie J; Allocco J; Sigmund J; Dorso K; de la Cruz M; Martín J; Vicente F; Genilloud O; Donald RG; Phillips JW Bioorg Med Chem Lett; 2012 Dec; 22(23):7127-30. PubMed ID: 23084277 [TBL] [Abstract][Full Text] [Related]
3. Discovery and development of kibdelomycin, a new class of broad-spectrum antibiotics targeting the clinically proven bacterial type II topoisomerase. Singh SB Bioorg Med Chem; 2016 Dec; 24(24):6291-6297. PubMed ID: 27143131 [TBL] [Abstract][Full Text] [Related]
4. Structures of kibdelomycin bound to Staphylococcus aureus GyrB and ParE showed a novel U-shaped binding mode. Lu J; Patel S; Sharma N; Soisson SM; Kishii R; Takei M; Fukuda Y; Lumb KJ; Singh SB ACS Chem Biol; 2014 Sep; 9(9):2023-31. PubMed ID: 24992706 [TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of α-substituted isonipecotic acid benzothiazole analogues as potent bacterial type II topoisomerase inhibitors. Axford LC; Agarwal PK; Anderson KH; Andrau LN; Atherall J; Barker S; Bennett JM; Blair M; Collins I; Czaplewski LG; Davies DT; Gannon CT; Kumar D; Lancett P; Logan A; Lunniss CJ; Mitchell DR; Offermann DA; Palmer JT; Palmer N; Pitt GR; Pommier S; Price D; Narasinga Rao B; Saxena R; Shukla T; Singh AK; Singh M; Srivastava A; Steele C; Stokes NR; Thomaides-Brears HB; Tyndall EM; Watson D; Haydon DJ Bioorg Med Chem Lett; 2013 Dec; 23(24):6598-603. PubMed ID: 24239017 [TBL] [Abstract][Full Text] [Related]
6. In Vitro and In Vivo Characterization of the Novel Oxabicyclooctane-Linked Bacterial Topoisomerase Inhibitor AM-8722, a Selective, Potent Inhibitor of Bacterial DNA Gyrase. Tan CM; Gill CJ; Wu J; Toussaint N; Yin J; Tsuchiya T; Garlisi CG; Kaelin D; Meinke PT; Miesel L; Olsen DB; Lagrutta A; Fukuda H; Kishii R; Takei M; Oohata K; Takeuchi T; Shibue T; Takano H; Nishimura A; Fukuda Y; Singh SB Antimicrob Agents Chemother; 2016 Aug; 60(8):4830-9. PubMed ID: 27246784 [TBL] [Abstract][Full Text] [Related]
7. Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE), Part II: development of inhibitors with broad spectrum, Gram-negative antibacterial activity. Trzoss M; Bensen DC; Li X; Chen Z; Lam T; Zhang J; Creighton CJ; Cunningham ML; Kwan B; Stidham M; Nelson K; Brown-Driver V; Castellano A; Shaw KJ; Lightstone FC; Wong SE; Nguyen TB; Finn J; Tari LW Bioorg Med Chem Lett; 2013 Mar; 23(5):1537-43. PubMed ID: 23294697 [TBL] [Abstract][Full Text] [Related]
8. Kibdelomycin is a bactericidal broad-spectrum aerobic antibacterial agent. Singh SB; Dayananth P; Balibar CJ; Garlisi CG; Lu J; Kishii R; Takei M; Fukuda Y; Ha S; Young K Antimicrob Agents Chemother; 2015; 59(6):3474-81. PubMed ID: 25845866 [TBL] [Abstract][Full Text] [Related]
9. Dual inhibition of Staphylococcus aureus DNA gyrase and topoisomerase IV activity by phenylalanine-derived (Z)-5-arylmethylidene rhodanines. Werner MM; Patel BA; Talele TT; Ashby CR; Li Z; Zauhar RJ Bioorg Med Chem; 2015 Sep; 23(18):6125-37. PubMed ID: 26320664 [TBL] [Abstract][Full Text] [Related]
10. Discovery of Benzothiazole Scaffold-Based DNA Gyrase B Inhibitors. Gjorgjieva M; Tomašič T; Barančokova M; Katsamakas S; Ilaš J; Tammela P; Peterlin Mašič L; Kikelj D J Med Chem; 2016 Oct; 59(19):8941-8954. PubMed ID: 27541007 [TBL] [Abstract][Full Text] [Related]
11. Novel 3-fluoro-6-methoxyquinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV. Mitton-Fry MJ; Brickner SJ; Hamel JC; Barham R; Brennan L; Casavant JM; Ding X; Finegan S; Hardink J; Hoang T; Huband MD; Maloney M; Marfat A; McCurdy SP; McLeod D; Subramanyam C; Plotkin M; Reilly U; Schafer J; Stone GG; Uccello DP; Wisialowski T; Yoon K; Zaniewski R; Zook C Bioorg Med Chem Lett; 2017 Aug; 27(15):3353-3358. PubMed ID: 28610977 [TBL] [Abstract][Full Text] [Related]
12. Novel quinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV. Mitton-Fry MJ; Brickner SJ; Hamel JC; Brennan L; Casavant JM; Chen M; Chen T; Ding X; Driscoll J; Hardink J; Hoang T; Hua E; Huband MD; Maloney M; Marfat A; McCurdy SP; McLeod D; Plotkin M; Reilly U; Robinson S; Schafer J; Shepard RM; Smith JF; Stone GG; Subramanyam C; Yoon K; Yuan W; Zaniewski RP; Zook C Bioorg Med Chem Lett; 2013 May; 23(10):2955-61. PubMed ID: 23566517 [TBL] [Abstract][Full Text] [Related]
13. Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE). Part I: Structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity. Tari LW; Trzoss M; Bensen DC; Li X; Chen Z; Lam T; Zhang J; Creighton CJ; Cunningham ML; Kwan B; Stidham M; Shaw KJ; Lightstone FC; Wong SE; Nguyen TB; Nix J; Finn J Bioorg Med Chem Lett; 2013 Mar; 23(5):1529-36. PubMed ID: 23352267 [TBL] [Abstract][Full Text] [Related]
14. Discovery of 4,5,6,7-Tetrahydrobenzo[1,2-d]thiazoles as Novel DNA Gyrase Inhibitors Targeting the ATP-Binding Site. Tomašič T; Katsamakas S; Hodnik Ž; Ilaš J; Brvar M; Solmajer T; Montalvão S; Tammela P; Banjanac M; Ergović G; Anderluh M; Peterlin Mašič L; Kikelj D J Med Chem; 2015 Jul; 58(14):5501-21. PubMed ID: 26098163 [TBL] [Abstract][Full Text] [Related]
16. New N-phenylpyrrolamide DNA gyrase B inhibitors: Optimization of efficacy and antibacterial activity. Durcik M; Lovison D; Skok Ž; Durante Cruz C; Tammela P; Tomašič T; Benedetto Tiz D; Draskovits G; Nyerges Á; Pál C; Ilaš J; Peterlin Mašič L; Kikelj D; Zidar N Eur J Med Chem; 2018 Jun; 154():117-132. PubMed ID: 29778894 [TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and antibacterial evaluation of new quinoline-1,3,4-oxadiazole and quinoline-1,2,4-triazole hybrids as potential inhibitors of DNA gyrase and topoisomerase IV. Hofny HA; Mohamed MFA; Gomaa HAM; Abdel-Aziz SA; Youssif BGM; El-Koussi NA; Aboraia AS Bioorg Chem; 2021 Jul; 112():104920. PubMed ID: 33910078 [TBL] [Abstract][Full Text] [Related]
18. Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus. Janupally R; Jeankumar VU; Bobesh KA; Soni V; Devi PB; Pulla VK; Suryadevara P; Chennubhotla KS; Kulkarni P; Yogeeswari P; Sriram D Bioorg Med Chem; 2014 Nov; 22(21):5970-87. PubMed ID: 25288496 [TBL] [Abstract][Full Text] [Related]
19. Tricyclic GyrB/ParE (TriBE) inhibitors: a new class of broad-spectrum dual-targeting antibacterial agents. Tari LW; Li X; Trzoss M; Bensen DC; Chen Z; Lam T; Zhang J; Lee SJ; Hough G; Phillipson D; Akers-Rodriguez S; Cunningham ML; Kwan BP; Nelson KJ; Castellano A; Locke JB; Brown-Driver V; Murphy TM; Ong VS; Pillar CM; Shinabarger DL; Nix J; Lightstone FC; Wong SE; Nguyen TB; Shaw KJ; Finn J PLoS One; 2013; 8(12):e84409. PubMed ID: 24386374 [TBL] [Abstract][Full Text] [Related]
20. Synthesis and Evaluation of N-Phenylpyrrolamides as DNA Gyrase B Inhibitors. Durcik M; Tammela P; Barančoková M; Tomašič T; Ilaš J; Kikelj D; Zidar N ChemMedChem; 2018 Jan; 13(2):186-198. PubMed ID: 29206345 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]